Original Article

You have free access to this content

Immunophenotyping is an independent factor for risk stratification in AML

  1. R. Repp1,*,
  2. U. Schaekel2,
  3. G. Helm1,
  4. C. Thiede2,
  5. S. Soucek2,
  6. U. Pascheberg3,
  7. H. Wandt4,
  8. W. Aulitzky5,
  9. H. Bodenstein6,
  10. R. Sonnen7,
  11. H. Link8,
  12. G. Ehninger2,
  13. M. Gramatzki1

Article first published online: 21 APR 2003

DOI: 10.1002/cyto.b.10030

Issue

Cytometry Part B: Clinical Cytometry

Cytometry Part B: Clinical Cytometry

Special Issue: Cytomics in Predictive Medicine

Volume 53B, Issue 1, pages 11–19, May 2003

Additional Information

How to Cite

Repp, R., Schaekel, U., Helm, G., Thiede, C., Soucek, S., Pascheberg, U., Wandt, H., Aulitzky, W., Bodenstein, H., Sonnen, R., Link, H., Ehninger, G. and Gramatzki, M. (2003), Immunophenotyping is an independent factor for risk stratification in AML. Cytometry, 53B: 11–19. doi: 10.1002/cyto.b.10030

Author Information

  1. 1

    Department of Medicine III, University of Erlangen-Nuremberg, Erlangen, Germany

  2. 2

    Department of Medicine I, University of Dresden, Dresden, Germany

  3. 3

    Dortmund, Germany

  4. 4

    Department of Medicine V, Klinikum Nuremberg, Nuremberg, Germany

  5. 5

    Department of Medicine II, Robert-Bosch Hospital, Stuttgart, Germany

  6. 6

    Department of Hematology/Oncology, Klinikum Minden, Minden, Germany

  7. 7

    Department of Hematology, Krankenhaus St. Georg, Hamburg, Germany

  8. 8

    Department of Medicine I, Westpfalz-Klinikum, Kaiserslautern, Germany

*Division of Hematology/Oncology, Department of Medicine III, Krankenhaustrasse 12, 91054 Erlangen, Germany

Publication History

  1. Issue published online: 21 APR 2003
  2. Article first published online: 21 APR 2003
  3. Manuscript Accepted: 14 FEB 2003
  4. Manuscript Received: 13 JAN 2003

Funded by

  • Deutsche Krebshilfe

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    XIAOQING LI, JUAN LI, WEN DU, JIAHUA ZHANG, WEI LIU, XIANGJUN CHEN, HONGRUI LI, SHIANG HUANG, XIN LI, Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia, APMIS, 2011, 119, 1
    Direct Link:
  2. 2
    Maha Atfy, Mohamad Eissa, Hossam E. Salah, Deena A. El Shabrawy, Role of urokinase plasminogen activator receptor (CD87) as a prognostic marker in acute myeloid leukemia, Medical Oncology, 2011,

    CrossRef

  3. 3
    Åsa Rangert Derolf, Elisabet Björklund, Joanna Mazur, Magnus Björkholm, Anna Porwit, Expression patterns of CD33 and CD15 predict outcome in patients with acute myeloid leukemia, Leukemia & Lymphoma, 2008, 49, 7, 1279

    CrossRef

  4. 4
    Pierre Champelovier, Michèle El Atifi, Virginie Pautre, Béatrice Rostaing, François Berger, Daniel Seigneurin, Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors, Experimental Hematology, 2008, 36, 1, 28

    CrossRef

  5. 5
    Denise M. Oliansky, Frederick Appelbaum, Peter A. Cassileth, Armand Keating, Jamie Kerr, Yago Nieto, Susan Stewart, Richard M. Stone, Martin S. Tallman, Philip L. McCarthy, Theresa Hahn, The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review, Biology of Blood and Marrow Transplantation, 2008, 14, 2, 137

    CrossRef

  6. 6
    Günter Valet, Cytomics as a new potential for drug discovery, Drug Discovery Today, 2006, 11, 17-18, 785

    CrossRef

  7. 7
    Attila Tárnok, Günther K. Valet, Frank Emmrich, Systems biology and clinical cytomics: The 10th Leipziger workshop and the 3rd international workshop on slide-based cytometry, Cytometry Part A, 2006, 69A, 1
    Direct Link:
  8. 8
    G. Perea, A. Domingo, N. Villamor, C. Palacios, J. Juncà, P. Torres, A. Llorente, C. Fernández, M. Tormo, M.P. Queipo de Llano, J. Bargay, M. Gallart, L. Florensa, P. Vivancos, J.M. Martí, Ll. Font, J. Berlanga, J. Esteve, J. Bueno, J.M. Ribera, S. Brunet, J. Sierra, J.F. Nomdedéu, Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients, Leukemia Research, 2005, 29, 10, 1109

    CrossRef

  9. 9
    Günter Valet, Human cytome project, cytomics, and systems biology: The incentive for new horizons in cytometry, Cytometry Part A, 2005, 64A, 1
    Direct Link:
  10. You have free access to this content10
    Günter K. Valet, Heinz Gert Hoeffkes, Data pattern analysis for the individualised pretherapeutic identification of high-risk diffuse large B-cell lymphoma (DLBCL) patients by cytomics, Cytometry Part A, 2004, 59A, 2
    Direct Link:
  11. 11
    Roberta Riccioni, Annalisa Rossini, Luana Calabrò, Daniela Diverio, Luca Pasquini, Francesco Lococo, Cesare Peschle, Ugo Testa, Immunophenotypic Features of Acute Myeloid Leukemias Overexpressing the Interleukin 3 Receptor Alpha Chain, Leukemia & Lymphoma, 2004, 45, 8, 1511

    CrossRef

  12. 12
    Current Awareness in Hematological Oncology, Hematological Oncology, 2003, 21, 4
    Direct Link:
  13. You have free access to this content13
    Günter K. Valet, Attila Tárnok, Cytomics in predictive medicine, Cytometry Part B: Clinical Cytometry, 2003, 53B, 1
    Direct Link:
  14. You have free access to this content14
    G. Valet, R. Repp, H. Link, A. Ehninger, M. Gramatzki M, Pretherapeutic identification of high-risk acute myeloid leukemia (AML) patients from immunophenotypic, cytogenetic, and clinical parameters, Cytometry Part B: Clinical Cytometry, 2003, 53B, 1
    Direct Link:
  15. 15
    Antigens,
    Direct Link:
View Full Article (HTML) Get PDF (132K)